IVA.PA

Inventiva S.A. [IVA.PA] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

IVA.PA Stock Summary

Top 10 Correlated ETFs

IVA.PA

Top 10 Correlated Stocks

IVA.PA

In the News

IVA.PA Financial details

Company Rating
-
Market Cap
175.97M
Income
-164.7M
Revenue
29.66M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
120
Optionable
No
Shortable
Yes
Earnings
27 Mar 2024
P/E
-3.07
Forward P/E
-
PEG
-0.17
P/S
17.2
P/B
3.66
P/C
-
P/FCF
-4.61
Quick Ratio
3.16
Current Ratio
3.47
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-3.74
EPS next Y
-
EPS next Q
-
EPS this Y
85.5%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
13.68%
Revenue last 5Y
20.09%
Revenue Q/Q
719.36%
EPS Q/Q
-14.5%
-
-
-
-
SMA20
12.68%
SMA50
36.4%
SMA100
28.51%
Inst Own
-
Inst Trans
-
ROA
-47%
ROE
-81%
ROC
-0.67%
Gross Margin
100%
Oper. Margin
-469%
Profit Margin
-446%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.88-4.84
52W High
-20.75%
52W Low
+217%
RSI
65.28
Rel Volume
0.3
Avg Volume
69.81K
Volume
21.02K
Perf Week
11.62%
Perf Month
14.86%
Perf Quarter
29.92%
Perf Half Y
28.86%
-
-
-
-
Beta
0.958
-
-
Volatility
0.05%, 0.19%
Prev Close
-2.46%
Price
3.17
Change
-2.46%

Something similar

Top by Market Cap
FXAIX
AAPL
1YD.DE
NVDA
VFINX
Top Correlated ETFs
PRAC.DE
UIMC.DE
ECRP.PA
PR1C.DE
TCC4.DE
Top Correlated Stocks
INSE.L
IAM.PA
EBQ.L
PAT.L
1011.HK
Similar Market Cap
SWRLX
FSBBX
1355.HK
FCIG.TO
6162.HK

Company Profile

Healthcare Biotechnology
  • Volume Average 69.81K
  • Market Capitalization 175.97M
  • Employee 120
  • CEO Dr. Pierre Broqua Ph.D.
  • Headquarters Daix,FR
  • IPO Date 2017-02-15
  • Website https://www.inventivapharma.com

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.